AbbVie Announces HUMIRA(R) (adalimumab) Global Patent License with Pfizer

NORTH CHICAGO, Ill., Nov. 30, 2018 -- (Healthcare Sales & Marketing Network) -- AbbVie (NYSE: ABBV) announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product. Under the terms of the agreements, AbbVie will grant... Biopharmaceuticals, Generics, Licensing AbbVie, Pfizer, biosimilar, HUMIRA, adalimumab
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news